We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > first-line

News List

FDA Approves Pembrolizumab for First-Line Treatment of HNSCC americanpharmaceuticalreview
June 13, 2019
The Food and Drug Administration (FDA) approved pembrolizumab (KEYTRUDA, Merck) for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
NICE rules against first-line use of Ipsen’s Cabometyx pharmatimes
June 06, 2018
The National Institute for Health and Care Excellence has issued a preliminary decision rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on the NHS.
Roche says first-line Tecentriq combination meets main goals in Phase III non-squamous NSCLC study firstwordpharma
May 30, 2018
Roche announced Phase III results Tuesday showing that patients with advanced non-squamous non-small-cell lung cancer (NSCLC) who took the company's PD-L1 inhibitor Tecentriq (atezolizumab) plus chemotherapy as a first-line treatment achieved significantl